The use of the sodium-glucose cotransporter-2 (SGLT2) inhibitor (SGLT2i) canagliflozin at 300 mg has been shown to correlate with a reduction in SWE values to a significant extent even in a population without diabetes [8]. The gene discussed is SLC5A2; the disease is diabetes mellitus.